IntelGenx announced the issuance of a patent from the United States Patent and Trademark Office covering the design and manufacturing of topical oral films for the local (topical) treatment of diseases of the oral mucosa using mucoadhesive particles.
IntelGenx (TSXV:IGX,OTCQX:IGXT) announced the issuance of a patent from the United States Patent and Trademark Office covering the design and manufacturing of topical oral films (TOF) for the local (topical) treatment of diseases of the oral mucosa using mucoadhesive particles.
As quoted in the press release:
This patent is in the same family as U.S. Patent 9,668,970 – issued to IntelGenx in June 2017 – and provides broader coverage for IntelGenx’s proprietary technology, which is intended to provide sustained release of an active agent to a target area of the oral cavity. The technology is useful for the topical treatment of oral diseases and conditions such as gingivitis, buccal ulcers, canker sores, Sjögren’s syndrome, oral mucositis and Behcet’s disease.
“This is the second orange book eligible U.S patent IntelGenx has been granted for our topical oral film technology, and it reflects our strategy to broaden and diversify our intellectual property portfolio to obtain protection for the many applications of our VersaFilm technology,” said Horst G. Zerbe, CEO of IntelGenx. “In this case, we believe our technology offers a novel and potentially superior treatment option for oral diseases such as Sjögren’s syndrome and oral mucositis, both of which represent significant unmet medical need and a large market opportunity.”